Adial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative Colitis
(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) announced Tuesday that Purnovate, Inc., a subsidiary of Adial, achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory bowel diseases.
PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases (IBD).
In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints, which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans.
Specially, PNV-6005 significantly prevented weight loss as compared to the control group (greater than 50% inhibition of weight loss). It also significantly prevented colon damage as evidenced by reduction of shortening of colon lengths in the PNV-6005 treated group (almost total prevention), as well as a decrease in inflammation as assessed histologically.
Adial Pharmaceuticals Names Director Tony Goodman As Chief Operating Officer
European Shares Set To Follow Wall Street Lower
Japan Private Sector Growth Weakest In 4 Months
Sensex, Nifty Extend Losses For Fourth Day
Australian Market Doubles Early Losses In Mid-market
Asian Markets Track Wall Street Lower
Sensex, Nifty Seen Lower On Weak Global Cues
